ArticleEJNMMI research2023
Optimization of the radiation dosimetry protocol in Lutetium-177-PSMA therapy: toward clinical implementation.
Article in EJNMMI research, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 26 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
26 citing papers in PubMed, 38 citations in OpenAlex.
- Outcome-driven dosimetry optimization for [European journal of nuclear medicine and molecular imaging · 2026Article
- Virtual-patient nonlinear mixed-effects modelling for data-driven optimisation of single-time-point dosimetry: a proof-of-concept study in [EJNMMI physics · 2026Article
- State-of-the-art and future developments in dosimetry for SSTR- and PSMA-targeting radioligand therapies.Zeitschrift fur medizinische Physik · 2026Review
- PROQURE-I: a phase I study adding concurrent [European journal of nuclear medicine and molecular imaging · 2026Article
- Inter-center variability of dosimetry methodology and the impact on reported absorbed dose for [European journal of nuclear medicine and molecular imaging · 2026Article
- Validation of Simplified Renal Dosimetry Protocols forMolecular imaging and radionuclide therapy · 2026Article
- Uncertainty analysis of single-time-point organ dosimetry compared with the multi-time-point method in radioimmunotherapy.EJNMMI physics · 2026Article
- Future of radiotheranostics.BMJ oncology · 2026Review
- Design and Evaluation of a Portable Pinhole SPECT System forDiagnostics (Basel, Switzerland) · 2025Article
- Characterization of Effective Half-Life for Instant Single-Time-Point Dosimetry Using Machine Learning.Journal of nuclear medicine : official publication, Society of Nuclear Medicine · 2025Article
- Accuracy and precision analyses of single-time-point dosimetry utilising physiologically-based pharmacokinetic modelling and non-linear mixed-effects modelling.EJNMMI physics · 2025Article
- On the reduction of imaging time-points for dosimetry in radionuclide therapy.EJNMMI physics · 2025Article
- A proof-of-concept study of personalized dosimetry for targeted radioligand therapy using pre-treatment diagnostic dynamic PET/CT and Monte Carlo simulation.Frontiers in oncology · 2025Article
- Targeted radionuclide therapy for gliomas: Emerging clinical trial landscape.Neuro-oncology · 2024Review
- Validation of dosimetry programs (Olinda & IDAC) for evaluation of absorbed dose inEJNMMI physics · 2024Article
- Impact of the Reference Multiple-Time-Point Dosimetry Protocol on the Validity of Single-Time-Point Dosimetry for [Journal of nuclear medicine : official publication, Society of Nuclear Medicine · 2024Article
- A review of 177Lu dosimetry workflows: how to reduce the imaging workloads?EJNMMI physics · 2024Review
- Organ and tumor dosimetry including method simplification for [EJNMMI physics · 2024Article
- Lutetium-177-Prostate-Specific Membrane Antigen Radioligand Therapy: What Is the Value of Post-Therapeutic Imaging?Biomedicines · 2024Review
- Bone marrow dosimetry in low volume mHSPC patients receiving Lu-177-PSMA therapy using SPECT/CT.EJNMMI physics · 2024Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundDosimetry in [
methodsTen patients with metastatic hormone-sensitive prostate cancer received two cycles of [
resultsAccurate lesion dosimetry is possible using one-time point SPECT imaging at 168 h, with an increase in uncertainty (20% vs. 14% for the reference standard). By including a second time point, uncertainty was comparable to the reference standard (13%). Organ dosimetry can be performed using a single SPECT at 24 h or 48 h. Dosimetry based on planar scans did not provide accurate dose estimations.
conclusionAccurate lesion dosimetry in [
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.